NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Go back to NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
(NASDAQ: NTHI) Delayed: 3.35 +0.09 (2.76%)
Previous Close $3.26    52 Week High
Open $3.30    52 Week Low
Day High $3.40    P/E N/A 
Day Low $3.28    EPS
Volume 23,408